HOUSE COMMERCE/OVERSIGHT SUBCOMMITTEE COUNSEL PATRICK McLAIN
Executive Summary
HOUSE COMMERCE/OVERSIGHT SUBCOMMITTEE COUNSEL PATRICK McLAIN is leaving Capitol Hill in February to become Senior VP of the Washington, D.C. management consultant firm Rowan & Blewitt. McLain served on the staff of Rep. Dingell's (D-Mich.) subcommittee for nearly 14 years. As subcommittee counsel, he was involved in several investigations related to the pharmaceutical industry, including oversight of FDA review of the AIDS products Virazole (by ICN subsidiary Viratek) and Imreg's Imreg-1. McLain also has been active in investigations of FDA's regulation of prescription drug advertising, health claims for food products, Rx-to-OTC switches, and the OTC Review.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth